A carregar...
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the trea...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2017
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486233/ https://ncbi.nlm.nih.gov/pubmed/29178444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010968.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|